A library of rationally designed multitarget PROTACs(exemplified by case (a) in Figure 5A) has been recently reported.59 Particularly, gefitinib and olaparib were combined in CRBN-basedor VHL-based PROTACs, with the intent to degrade two targets interconnectedin cancer evolution pathways, i.e., the epidermal growth factor receptor(EGFR) and poly(ADP-ribose) polymerase (PARP), respectively (Figure 6). This evidence concerns the gene EGFR and cancer.